Molecular Oncology Diagnostics Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Product Type (Instruments, Kits and Assays, Software), By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other Technologies), By Application (Research, Clinical), By Cancer Type ({Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood Cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)}, By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes), By Region and Competition, 2020-2030F
Market Overview
The Global Molecular Oncology Diagnostics Market was valued at USD 3.54 billion in 2024 and is projected to reach USD 7.84 billion by 2030, growing at a CAGR of 14.17% during the forecast period. The market is expanding rapidly due to the rising incidence of chronic diseases, particularly cancer, which is driving the demand for advanced diagnostic solutions. Molecular oncology diagnostics refer to specialized tests used to detect cancer at the molecular level, identifying genetic materials, proteins, and biomarkers that signal the presence of disease. This approach supports early detection, targeted therapy, and improved patient outcomes. Increased awareness, advances in technology such as next-generation sequencing (NGS), and growing investments in personalized medicine are all contributing to market growth. In addition, stringent regulatory frameworks and a global shift toward precision oncology are encouraging innovation in molecular diagnostic platforms. As healthcare systems worldwide emphasize early detection and efficient disease management, the molecular oncology diagnostics market is poised for sustained expansion across developed and emerging regions.
Key Market Drivers
Increasing Global Cancer Incidence and Demand for Early Detection
The rising global prevalence of cancer is a major factor propelling growth in the molecular oncology diagnostics market. According to the World Health Organization (WHO), nearly 10 million people died from cancer in 2020, with the incidence rate expected to rise by 47% by 2040, reaching over 28 million new cases annually. This alarming increase has led to a heightened focus on early detection and precision diagnostics to improve treatment outcomes and reduce healthcare burdens. Molecular diagnostics offer a pathway for identifying cancer-related mutations, chromosomal changes, and gene expression profiles even before clinical symptoms appear. Technologies like PCR, NGS, and microarrays are pivotal in enabling personalized treatment strategies and enhancing prognosis accuracy. Governments and research bodies are investing heavily in cancer diagnostics infrastructure; for example, the U.S. National Cancer Institute allocated over $7 billion in 2023 for cancer research, with a strong emphasis on molecular diagnostic tools. These developments underscore the growing importance of molecular oncology diagnostics in combating the global cancer burden.
Key Market Challenges
High Cost and Limited Accessibility of Advanced Diagnostic Technologies
Despite technological progress, the high cost of molecular oncology diagnostics remains a critical barrier to widespread adoption. Advanced testing methods like next-generation sequencing and multiplex PCR panels require expensive reagents, equipment, and skilled professionals, making them inaccessible in many low- and middle-income countries. A single NGS test can cost between $1,000 and $5,000, limiting affordability for patients and straining underfunded healthcare systems. Furthermore, insufficient diagnostic infrastructure, particularly in rural areas, exacerbates disparities in healthcare access. Challenges include a lack of molecular pathology labs, inadequate cold chain systems, and a shortage of trained personnel. Even in developed nations, inconsistent reimbursement policies hinder the adoption of newer molecular tests. According to the World Bank, healthcare expenditure in low-income nations averages about 5% of GDP, compared to more than 10% in high-income countries. This disparity underscores the urgent need for policy support, public-private partnerships, and cost-reduction strategies to bridge the accessibility gap in molecular diagnostics.
Key Market Trends
Integration of Artificial Intelligence and Machine Learning in Molecular Diagnostics
A transformative trend in the molecular oncology diagnostics market is the integration of artificial intelligence (AI) and machine learning (ML) technologies to streamline and enhance genomic data analysis. As diagnostic platforms generate increasingly complex datasets, AI and ML provide tools to analyze patterns, classify cancer subtypes, and predict patient responses more accurately and rapidly than manual methods. These technologies can process thousands of variants simultaneously, identifying clinically relevant mutations and helping in treatment selection. Deep learning models are also being used to enhance the accuracy of image-based diagnostics and to interpret multi-omics data in real-time. Governments are supporting AI development through major funding initiatives, such as the NIH’s Bridge2AI program in the U.S. and the UK's Industrial Strategy Challenge Fund. These efforts are catalyzing the adoption of AI-driven diagnostics, making molecular oncology testing more efficient, scalable, and accessible across the globe.
Key Market Players
Report Scope:
In this report, the Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Molecular Oncology Diagnostics Market.
Available Customizations:
Global Molecular Oncology Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
The Global Molecular Oncology Diagnostics Market was valued at USD 3.54 billion in 2024 and is projected to reach USD 7.84 billion by 2030, growing at a CAGR of 14.17% during the forecast period. The market is expanding rapidly due to the rising incidence of chronic diseases, particularly cancer, which is driving the demand for advanced diagnostic solutions. Molecular oncology diagnostics refer to specialized tests used to detect cancer at the molecular level, identifying genetic materials, proteins, and biomarkers that signal the presence of disease. This approach supports early detection, targeted therapy, and improved patient outcomes. Increased awareness, advances in technology such as next-generation sequencing (NGS), and growing investments in personalized medicine are all contributing to market growth. In addition, stringent regulatory frameworks and a global shift toward precision oncology are encouraging innovation in molecular diagnostic platforms. As healthcare systems worldwide emphasize early detection and efficient disease management, the molecular oncology diagnostics market is poised for sustained expansion across developed and emerging regions.
Key Market Drivers
Increasing Global Cancer Incidence and Demand for Early Detection
The rising global prevalence of cancer is a major factor propelling growth in the molecular oncology diagnostics market. According to the World Health Organization (WHO), nearly 10 million people died from cancer in 2020, with the incidence rate expected to rise by 47% by 2040, reaching over 28 million new cases annually. This alarming increase has led to a heightened focus on early detection and precision diagnostics to improve treatment outcomes and reduce healthcare burdens. Molecular diagnostics offer a pathway for identifying cancer-related mutations, chromosomal changes, and gene expression profiles even before clinical symptoms appear. Technologies like PCR, NGS, and microarrays are pivotal in enabling personalized treatment strategies and enhancing prognosis accuracy. Governments and research bodies are investing heavily in cancer diagnostics infrastructure; for example, the U.S. National Cancer Institute allocated over $7 billion in 2023 for cancer research, with a strong emphasis on molecular diagnostic tools. These developments underscore the growing importance of molecular oncology diagnostics in combating the global cancer burden.
Key Market Challenges
High Cost and Limited Accessibility of Advanced Diagnostic Technologies
Despite technological progress, the high cost of molecular oncology diagnostics remains a critical barrier to widespread adoption. Advanced testing methods like next-generation sequencing and multiplex PCR panels require expensive reagents, equipment, and skilled professionals, making them inaccessible in many low- and middle-income countries. A single NGS test can cost between $1,000 and $5,000, limiting affordability for patients and straining underfunded healthcare systems. Furthermore, insufficient diagnostic infrastructure, particularly in rural areas, exacerbates disparities in healthcare access. Challenges include a lack of molecular pathology labs, inadequate cold chain systems, and a shortage of trained personnel. Even in developed nations, inconsistent reimbursement policies hinder the adoption of newer molecular tests. According to the World Bank, healthcare expenditure in low-income nations averages about 5% of GDP, compared to more than 10% in high-income countries. This disparity underscores the urgent need for policy support, public-private partnerships, and cost-reduction strategies to bridge the accessibility gap in molecular diagnostics.
Key Market Trends
Integration of Artificial Intelligence and Machine Learning in Molecular Diagnostics
A transformative trend in the molecular oncology diagnostics market is the integration of artificial intelligence (AI) and machine learning (ML) technologies to streamline and enhance genomic data analysis. As diagnostic platforms generate increasingly complex datasets, AI and ML provide tools to analyze patterns, classify cancer subtypes, and predict patient responses more accurately and rapidly than manual methods. These technologies can process thousands of variants simultaneously, identifying clinically relevant mutations and helping in treatment selection. Deep learning models are also being used to enhance the accuracy of image-based diagnostics and to interpret multi-omics data in real-time. Governments are supporting AI development through major funding initiatives, such as the NIH’s Bridge2AI program in the U.S. and the UK's Industrial Strategy Challenge Fund. These efforts are catalyzing the adoption of AI-driven diagnostics, making molecular oncology testing more efficient, scalable, and accessible across the globe.
Key Market Players
- Sysmex Corporation
- F. Hoffmann-La Roche Ltd.
- Myriad Genetics, Inc.
- HTG Molecular Diagnostics, Inc.
- Danaher Corporation
- QIAGEN N.V.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Illumina, Inc.
- Bayer AG
Report Scope:
In this report, the Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Molecular Oncology Diagnostics Market, By Product Type:
- Instruments
- Kits and Assays
- Software
- Molecular Oncology Diagnostics Market, By Technology:
- Fluorescence In-Situ Hybridization (FISH)
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- Flow Cytometry
- Other Technologies
- Molecular Oncology Diagnostics Market, By Application:
- Research
- Clinical
- Molecular Oncology Diagnostics Market, By Cancer Type:
- Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors)
- Blood Cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)
- Molecular Oncology Diagnostics Market, By End User:
- Hospitals and Diagnostic Centers
- Reference Laboratories
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Molecular Oncology Diagnostics Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Molecular Oncology Diagnostics Market.
Available Customizations:
Global Molecular Oncology Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Instruments, Kits and Assays, Software)
5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other Technologies)
5.2.3. By Application (Research, Clinical)
5.2.4. By Cancer Type {Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)}
5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes)
5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)
5.2.7. By Company (2024)
5.3. Market Map
5.3.1. By Product Type
5.3.2. By Technology
5.3.3. By Application
5.3.4. By Cancer Type
5.3.5. By End User
5.3.6. By Region
6. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Technology
6.2.3. By Application
6.2.4. By Cancer Type
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Molecular Oncology Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Application
6.3.1.2.4. By Cancer Type
6.3.1.2.5. By End User
6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Application
6.3.2.2.4. By Cancer Type
6.3.2.2.5. By End User
6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Application
6.3.3.2.4. By Cancer Type
6.3.3.2.5. By End User
7. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Technology
7.2.3. By Application
7.2.4. By Cancer Type
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Application
7.3.1.2.4. By Cancer Type
7.3.1.2.5. By End User
7.3.2. France Molecular Oncology Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Application
7.3.2.2.4. By Cancer Type
7.3.2.2.5. By End User
7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Application
7.3.3.2.4. By Cancer Type
7.3.3.2.5. By End User
7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Application
7.3.4.2.4. By Cancer Type
7.3.4.2.5. By End User
7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Application
7.3.5.2.4. By Cancer Type
7.3.5.2.5. By End User
8. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Technology
8.2.3. By Application
8.2.4. By Cancer Type
8.2.5. By End User
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Molecular Oncology Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Application
8.3.1.2.4. By Cancer Type
8.3.1.2.5. By End User
8.3.2. Japan Molecular Oncology Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Application
8.3.2.2.4. By Cancer Type
8.3.2.2.5. By End User
8.3.3. India Molecular Oncology Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Application
8.3.3.2.4. By Cancer Type
8.3.3.2.5. By End User
8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Application
8.3.4.2.4. By Cancer Type
8.3.4.2.5. By End User
8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Application
8.3.5.2.4. By Cancer Type
8.3.5.2.5. By End User
9. SOUTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Technology
9.2.3. By Application
9.2.4. By Cancer Type
9.2.5. By End User
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Application
9.3.1.2.4. By Cancer Type
9.3.1.2.5. By End User
9.3.2. Argentina Molecular Oncology Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Application
9.3.2.2.4. By Cancer Type
9.3.2.2.5. By End User
9.3.3. Colombia Molecular Oncology Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Application
9.3.3.2.4. By Cancer Type
9.3.3.2.5. By End User
10. MIDDLE EAST AND AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Technology
10.2.3. By Application
10.2.4. By Cancer Type
10.2.5. By End User
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. UAE Molecular Oncology Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Application
10.3.1.2.4. By Cancer Type
10.3.1.2.5. By End User
10.3.2. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Technology
10.3.2.2.3. By Application
10.3.2.2.4. By Cancer Type
10.3.2.2.5. By End User
10.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Technology
10.3.3.2.3. By Application
10.3.3.2.4. By Cancer Type
10.3.3.2.5. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. PORTERS FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products/Services
14. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET: SWOT ANALYSIS
15. COMPETITIVE LANDSCAPE
15.1. Sysmex Corporation
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Myriad Genetics, Inc.
15.4. HTG Molecular Diagnostics, Inc.
15.5. Danaher Corporation
15.6. QIAGEN N.V.
15.7. Bio-Rad Laboratories, Inc.
15.8. Agilent Technologies, Inc.
15.9. Illumina, Inc.
15.10. Bayer AG
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Instruments, Kits and Assays, Software)
5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other Technologies)
5.2.3. By Application (Research, Clinical)
5.2.4. By Cancer Type {Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)}
5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes)
5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)
5.2.7. By Company (2024)
5.3. Market Map
5.3.1. By Product Type
5.3.2. By Technology
5.3.3. By Application
5.3.4. By Cancer Type
5.3.5. By End User
5.3.6. By Region
6. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Technology
6.2.3. By Application
6.2.4. By Cancer Type
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Molecular Oncology Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Application
6.3.1.2.4. By Cancer Type
6.3.1.2.5. By End User
6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Application
6.3.2.2.4. By Cancer Type
6.3.2.2.5. By End User
6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Application
6.3.3.2.4. By Cancer Type
6.3.3.2.5. By End User
7. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Technology
7.2.3. By Application
7.2.4. By Cancer Type
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Application
7.3.1.2.4. By Cancer Type
7.3.1.2.5. By End User
7.3.2. France Molecular Oncology Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Application
7.3.2.2.4. By Cancer Type
7.3.2.2.5. By End User
7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Application
7.3.3.2.4. By Cancer Type
7.3.3.2.5. By End User
7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Application
7.3.4.2.4. By Cancer Type
7.3.4.2.5. By End User
7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Application
7.3.5.2.4. By Cancer Type
7.3.5.2.5. By End User
8. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Technology
8.2.3. By Application
8.2.4. By Cancer Type
8.2.5. By End User
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Molecular Oncology Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Application
8.3.1.2.4. By Cancer Type
8.3.1.2.5. By End User
8.3.2. Japan Molecular Oncology Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Application
8.3.2.2.4. By Cancer Type
8.3.2.2.5. By End User
8.3.3. India Molecular Oncology Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Application
8.3.3.2.4. By Cancer Type
8.3.3.2.5. By End User
8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Application
8.3.4.2.4. By Cancer Type
8.3.4.2.5. By End User
8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Application
8.3.5.2.4. By Cancer Type
8.3.5.2.5. By End User
9. SOUTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Technology
9.2.3. By Application
9.2.4. By Cancer Type
9.2.5. By End User
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Application
9.3.1.2.4. By Cancer Type
9.3.1.2.5. By End User
9.3.2. Argentina Molecular Oncology Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Application
9.3.2.2.4. By Cancer Type
9.3.2.2.5. By End User
9.3.3. Colombia Molecular Oncology Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Application
9.3.3.2.4. By Cancer Type
9.3.3.2.5. By End User
10. MIDDLE EAST AND AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Technology
10.2.3. By Application
10.2.4. By Cancer Type
10.2.5. By End User
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. UAE Molecular Oncology Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Application
10.3.1.2.4. By Cancer Type
10.3.1.2.5. By End User
10.3.2. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Technology
10.3.2.2.3. By Application
10.3.2.2.4. By Cancer Type
10.3.2.2.5. By End User
10.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Technology
10.3.3.2.3. By Application
10.3.3.2.4. By Cancer Type
10.3.3.2.5. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. PORTERS FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products/Services
14. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET: SWOT ANALYSIS
15. COMPETITIVE LANDSCAPE
15.1. Sysmex Corporation
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Myriad Genetics, Inc.
15.4. HTG Molecular Diagnostics, Inc.
15.5. Danaher Corporation
15.6. QIAGEN N.V.
15.7. Bio-Rad Laboratories, Inc.
15.8. Agilent Technologies, Inc.
15.9. Illumina, Inc.
15.10. Bayer AG
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
